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were recruited. Doses of doxorubicin ranged from 10.4 to 
57.7 mg/m2. Blood samples for measurement of doxoru-
bicin and its metabolite doxorubicinol were collected after 
two administrations, with five samples collected in chil-
dren <3 years and eight in children ≥3 years. A population 
pharmacokinetic approach was used for analysis, including 
pharmacogenetic covariates. Natriuretic peptides and car-
diac troponins were measured to evaluate their role as early 
indicators of cardiotoxicity.
Results Age dependence of doxorubicin clearance was 
demonstrated, with children less than 3 years having a sta-
tistically significant lower clearance (21.1 ± 5.8 l/h/m2) 
than older children (26.6 ± 6.7 l/h/m2) (p = 0.0004) after 
correcting for body surface area. No effect of the investi-
gated genetic polymorphisms on the pharmacokinetics 
could be observed. Although natriuretic peptides were tran-
siently elevated after each doxorubicin administration and 
troponin levels increased with increasing doxorubicin expo-
sure, only limited correlation could be observed between 
their blood levels and doxorubicin pharmacokinetics.
Abstract 
Purpose Doxorubicin is a key component in many pedi-
atric oncology treatment regimens; still pharmacology 
data on which current dosing regimens are based are very 
limited.
Methods We conducted a multinational pharmacokinetic 
study investigating age dependency of doxorubicin metab-
olism and elimination in children with cancer. One hun-
dred and one patients treated with doxorubicin according 
to a cancer-specific national or European therapeutic trial 
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Conclusion In the European framework of funding and 
regulatory support, an add-on study to existing therapeutic 
trials was developed. The pediatric need concerning miss-
ing PK data could be addressed with limited burden for the 
patients. Empirically used dose adaptations for infants were 
generally found to be justified based on our PK analyses.
Keywords Doxorubicin · Cancer · Children · 
Pharmacokinetic · Cardiotoxicity
Introduction
Doxorubicin is included in a wide variety of cancer treat-
ment protocols for children and adults. As with other 
anticancer agents, doxorubicin has a narrow therapeutic 
window and serious side effects, including myelosuppres-
sion, mucositis and cardiotoxicity. Late-onset cardiotoxic-
ity presents a major problem of doxorubicin therapy since 
it might lead to congestive heart failure years after end of 
therapy sometimes without prior clinical symptoms.
Late subclinical effects, i.e., abnormal left ventricu-
lar structure and function, might affect more than 50 % of 
childhood cancer survivors, whereas clinical events might 
occur to 1–10 % [1]. Known risk factors include cumula-
tive dosage, younger age, use of concomitant cardiotoxic 
therapies, female sex and higher dose intensity [2]. Several 
genetic markers such as SLC28A3 and UGT1A6 are also 
discussed [3, 4].
Standard echocardiographic monitoring is not sensi-
tive enough to detect early subclinical deteriorations of the 
heart, and the positive predictive value is not sufficient for 
late heart failure. Therefore, more sensitive markers are 
necessary. Potential candidates are the cardiac isoforms of 
troponins, cardiac troponin T (cTnT) and I (cTnI), that are 
specific and sensitive biomarkers of myocardial cell injury 
[5–7], as well as the natriuretic peptides ANP (A-type 
natriuretic peptide) and BNP (B-type natriuretic peptide). 
The latter as well as their precursors NT-proANP (N-ter-
minal-proANP) and NT-proBNP (N-terminal-pro BNP) are 
peptide hormones that are secreted by the atria or ventri-
cle after increased pressure on the heart wall and myocyte 
stretch [8, 9].
Despite its frequent use, the pharmacokinetics of doxo-
rubicin have never been studied systematically in children. 
There are only few studies in the literature, and those have 
included only low numbers of patients and used limited 
sampling schedules.
The therapeutic window for doxorubicin dosing is nar-
row, and a better understanding of doxorubicin pharma-
cokinetics in children is thus crucial specifically for the 
very young. This deficit in information for the safe use of 
doxorubicin encouraged the European Medicines Agency 
(EMA) to place doxorubicin on the “Priority List” (Doc. 
Ref. EMEA/197972/2007, London, June 2007) for medica-
tions with a high priority for further research on pediatric 
use of the medicinal product. This list was a basis for appli-
cation and subsequent funding within the European Union 
7th Framework call “HEALTH-2007-4.2-1: Adapting off-
patent medicines to the specific needs of pediatric popula-
tions.” Within that call, the European Pediatric Oncology 
Off-patent Medicines Consortium (EPOC) applied and 
obtained funding. The consortium organized a European 
multinational and multicenter trial called the “Doxo”-study.
The primary objective was to evaluate age dependency 
in pharmacokinetics of doxorubicin in children and adoles-
cents. As secondary objectives, genetic polymorphisms that 
could influence doxorubicin clearance were investigated 
as well as the potential role of natriuretic peptides and tro-
ponin as indicators for subclinical cardiotoxicity.
Patients and methods
Study population
Children with solid tumors or leukemia were enrolled 
between April 2010 and October 2012 in 20 hospitals from 
four European countries (Germany, France, Italy and UK). 
Eligible patients were younger than 18 years and were 
planned to receive two or more cycles of doxorubicin for 
treatment of their disease. To be eligible, children three 
years and older had to be enrolled in a national or European 
protocol for treatment of Wilms tumor, neuroblastoma, soft 
tissue sarcoma, Ewing sarcoma or acute lymphoblastic leu-
kemia. Children younger than three years had to be enrolled 
or listed in any national or European study protocol for any 
pediatric malignancy. Additional blood withdrawal had to 
be acceptable for the patient, and assent was obtained from 
patients deemed to be able to assent. Written informed con-
sent was obtained from their parents or legal guardians.
Study organization
Sponsorship for the EPOC-MS-001-Doxo-Trial (EudraCT-
Nr: 2009-011454-17, ClinicalTrials.gov Identifier: 
NCT01095926) was provided by the University Hospital 
Münster, Germany, and national study managers (NSM) 
set up the clinical network and dealt with regulatory and 
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ethical issues in their respective countries. An independent 
Data Monitoring Committee reviewed patient safety data 
and overall data quality. The study was run in accordance 
with the Declaration of Helsinki, in compliance with the 
International Conference on Harmonization Good Clini-
cal Practice (GCP) Guidelines and applicable local regula-
tory requirements and laws. The study was approved by all 
nationally and locally responsible ethics committees.
Study endpoints
The primary endpoint was to determine whether there is 
a difference in doxorubicin clearance between children 
<3 years and children 3 to <18 years. Additional analyses 
were performed to assess the interindividual, intraindivid-
ual and residual variability of doxorubicin pharmacokinetic 
(PK) parameters in children and to assess the relationship 
between PK parameters and patient characteristics, includ-
ing genetic polymorphisms that may influence doxorubicin 
clearance (CL). Furthermore, kinetics of natriuretic pep-
tides and troponins were measured to explore their poten-
tial role as indicators for subclinical cardiotoxicity.
Doxorubicin administration
Patients received doxorubicin intravenously according 
to the treatment protocol for their tumor entity. Infusion 
durations ranged from 30 min to 48 h and mirrored usual 
clinical practice (see Online Resource 2 for more informa-
tion on doxorubicin dosage and infusion times used in the 
various treatment regimens). To harmonize practical issues 
concerning doxorubicin administration, a precise working 
procedure was provided to the participating centers. Herein, 
the use of a syringe-driven infusion system or at least a sys-
tem with a line volume from infusion bag to patient being 
less than 10 % of the doxorubicin volume was mandated.
PK, biomarker and pharmacogenetic assessments
Blood for analysis of doxorubicin and doxorubicinol 
concentrations was obtained during and up to 24 h after 
doxorubicin administration during two cycles chosen by 
the investigator. A pharmacokinetic dataset of five sam-
ples [3 + 2 (first + second sampling period)] was col-
lected in children <3 years and eight samples (5 + 3) in 
older children. The first sample of each cycle was taken 
during doxorubicin infusion and had to be taken by capil-
lary or peripheral blood sampling, whereas all other sam-
ples were taken after the end of doxorubicin administration 
and could thus be taken from the central venous catheter 
(CVC) which was also used for doxorubicin administra-
tion. Clear guidelines for CVC cleaning and blood sam-
pling had to be followed. Blood was collected into EDTA 
(ethylenediaminetetraacetate) tubes, put immediately on 
ice and centrifuged within 15 min at 1600g for 5 min at 
4 °C. Plasma had to be kept at −20 °C or lower until analy-
sis. Samples were sent from the clinical centers to the NSM 
for quality checks and from there passed on to the labora-
tory in Münster for analysis.
Doxorubicin and doxorubicinol concentrations were 
measured using a validated HPLC (high-performance liq-
uid chromatography) method (as described in detail before 
[10]) and were analyzed by population pharmacokinetic 
methods using nonlinear mixed-effects modeling (NON-
MEM) [11].
Natriuretic peptides and cardiac troponins were meas-
ured in plasma using commercially available enzyme-
linked immunosorbent assay kits (cTnT: troponin T hs, 
Roche Diagnostics GmbH, Mannheim, Germany/proANP 
(1–98): Biomedica Medizinprodukte, Wien/cTnI: TnI-
Ultra, ADVIA Centaur, BNP: ADVIA Centaur and NT-
proBNP: Immulite 2500, all three from Siemens Health-
care Diagnostics, Tarrytown, NY, USA). Samples were 
taken before doxorubicin administration and together with 
the last PK sample of each cycle. A fifth sample was taken 
2–4 weeks after doxorubicin administration in the second 
sampling cycle (Fig. 1). Blood was collected into EDTA 
tubes and centrifuged at 1600g for 5 min at room tem-
perature. Plasma had to be kept at −20 °C or lower until 
analysis.
Whole-blood (EDTA) samples for pharmacogenetic 
analysis were collected, frozen and shipped to the labora-
tory in Newcastle for analysis.
Echocardiographic measurements
Left ventricular shortening fraction (LVSF) was determined 
by echocardiograms before and after the two investigated 
doxorubicin administrations. “After” was defined as before 
the next protocol block containing doxorubicin, but not 
later than 28 days after doxorubicin administration.
Statistical analysis
The primary objective was to compare the distributions 
of the BSA-normalized clearance of the two age groups 
(group A: <3 years, group B: 3 to <18 years). The sample 
size calculation was based on the assumption that the rela-
tive clearance in both age groups follows a log-normal dis-
tribution. Since Frost et al. [12] found a between-subject 
variation in clearance/m2 (CLBSA) of 46 %, the standard 
deviation was assumed to be 0.46 in both groups. Given 
at least 20 patients in age group A and 80 patients in age 
group B, the calculated power to detect a difference of 39 % 
was 90 % for a two-sided unpaired t test with level of sig-
nificance 5 %. During analysis, the empirical distributions 
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of the logarithmized and non-logarithmized CLBSA values 
suggested that the assumption of normality was more justi-
fiable for the original, non-logarithmized CLBSA values. We 
therefore performed the t test on the original CLBSA data. 
Since the empirical variances of the CLBSA values differed 
considerably between age group A and B, Welch’s t test for 
groups with unequal variances was applied.
The statistical analyses of the secondary objectives were 
carried out using statistical key figures like mean and stand-
ard deviation, empirical quantiles and Spearman’s rank cor-
relation coefficient, as well as scatter and box-and-whisker 
plots.
Moreover, statistical tests were performed and are 
reported to be (statistically) noticeable if a p value is 
smaller than 5 %. The term significant is avoided since the 
p values resulted from explorative analyses and were not 
adjusted for multiple testing. All statistical analyses were 
conducted using the statistical software R [13] and vali-
dated by at least one further statistician.
Results
Trial conduction and patient characteristics
In total, 110 patients consented to participate in the trial 
with nine patients being excluded before any baseline data 
were recorded and plasma samples taken. From the 101 
patients, 94 patients contributed to PK analysis and 98 to 
biomarker and pharmacogenetic analysis. An overview of 
the patient demographics and clinical characteristics is pre-
sented in Table 1. Although patients with abnormal liver 
function were eligible for the study, none of the recruited 
patients had a serum bilirubin level above 1.2 mg/100 ml, 
which would have required a reduction of doxorubicin 
dose.
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Fig. 1  Study design (sampling scheme for patients >3 years). Sim-
plified overview of the main trial procedures, including pharmacoki-
netic and natriuretic peptides/troponin sampling times (termed A–E) 
as well as echocardiography schedules (termed 1.1–2.2). Sampling 
had to be done from two different chemotherapy blocks chosen by the 
investigator. Sampling schemes for patients <3 years were identical, 
with the exception that only 5 PK samples (3 + 2) were requested
Table 1  Demographics and clinical characteristics of recruited 
patients
Total <3 years 3 to <18 years
No. of patients 101 27 74
Age (years)
Median 5.3 1.6 7.3
Range 0.2–17.7 0.2–2.9 3.0–17.7
Height (cm)
Median 111.5 84 129
Range 52–194 52–97 89–194
Weight (kg)
Median 19.2 11.1 26
Range 3.6–88.1 3.6–14.7 111.5–88.1
Doxorubicin dose (mg/m2)
Median 28.7 29.1 28.6
Range 10.4–57.7 10.4–57.7 18.2–56.8
Doxorubicin infusion duration (h)
Median 3.88 3.95 3.88
Range 0.25–24.02 0.25–24 0.28–24.02
Gender
Male 50 11 39
Female 51 16 35
Tumor type
Wilms tumor 12 3 9
Neuroblastoma 9 4 5
Ewing sarcoma 27 1 26
Soft tissue sarcoma 16 5 11
ALL 30 7 23
Other 7 7 0
Country
France 24 6 18
Germany 29 6 23
Italy 27 10 17
UK 21 6 15
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Seven patients dropped out after the first sampling 
period. Reasons were disease progression or relapse 
(n = 4), problems with blood sampling from central venous 
catheter (n = 1) or withdrawal of consent (n = 2) (see 
Online Resource 1).
Doxorubicin pharmacokinetic analysis
Determination of the optimal PK sampling time points for 
the trial was based on a model derived from adult data [14]. 
An initial population pharmacokinetic model for doxoru-
bicin and doxorubicinol in children was set up from data-
sets of three earlier studies (two adults and one child) using 
NONMEM® 7.2. The model-building strategy for children 
>3 years has been described in detail before [11]. A pre-
planned interim analysis was performed after 30 patients to 
check the chosen sampling time points and readdress the 
number of samples and patients. The analysis did not lead 
to any protocol changes or amendments.
At the end of the trial, the model from the interim anal-
ysis was further adjusted to deliver a final PK model for 
doxorubicin and doxorubicinol in children. The final doxo-
rubicin model was a three-compartment model scaled on 
BSA with an additional power function of age on the CL 
of the parent compound. An additional compartment for 
doxorubicinol was added to the final doxorubicin model 
in order to describe the PK of the metabolite. No covari-
ate was able to improve the doxorubicinol model. A more 
detailed description of the model-building process was 
recently published [15].
Doxorubicin plasma concentration time curves esti-
mated by the PK model for four different patients are 
shown in Fig. 2. To show that the model was able to predict 
actual plasma concentrations for different infusion dura-
tions as well as for patients of different ages, we choose 
two different diseases (soft tissue sarcoma and ALL) with 
different infusion durations (4 and 1 h, respectively) and 
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Time aer dose [h]
T ½ alpha: 0.110h
T ½ beta: 2.0 h
T ½ gamma: 29 h
T ½ alpha: 0.124 h
T ½ beta: 2.0 h
T ½ gamma: 32 h
T ½ alpha: 0.079h
T ½ beta: 1.8 h
T ½ gamma: 21 h
T ½ alpha: 0.10 h
T ½ beta: 1.9 h
T ½ gamma: 30 h
Fig. 2  Plasma concentration time curves. Doxorubicin plasma con-
centration time curves estimated by the PopPK model of the first 
sampling period for four different patients are shown together with 
the corresponding doxorubicin plasma concentration half-lives. 
The open circles present the actual measured values. A and B were 
patients with soft tissue sarcoma and a scheduled infusion duration 
of 4 h. Patient A was 12.99 years old and patient B 0.66 years. The 
actual infusion time for patient B was 4.77 h. C and D were patients 
with ALL and a scheduled infusion duration of 1 h. Patient C was 
12.89 years and patient D 2.09 years. The actual infusion time for D 
was 1.04 h
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older than 12 years. The open circles represent the actual 
measured values. For each patient, the corresponding dis-
tribution, elimination and terminal phase elimination half-
lives are listed. Mean half-lives for all patients were: T½α: 
0.101 h, T½β: 2.0 h, T½γ: 31 h.
The mean value for CLBSA of both sampling periods was 
calculated for each patient using the NONMEM output 
tables. Comparison of CLBSA between the two age groups 
(group A: <3 years, group B: 3 to <18 years) using the two-
sided unpaired t test delivered a p value of 0.0004 indicat-
ing a significant difference. The mean CLBSA is 26.6 L/h/
m2 in age group A and 21.1 l/h/m2 in age group B, indi-
cating that the CL of children <3 years is lower than the 
relative clearance of children between 3 and 18 years (see 
Fig. 3).
Two further tests were performed to confirm this result 
by means of a sensitivity analysis. Welch’s t test on the log-
arithmized CLBSA data showed a p value of around 0.0039, 
and the p value of the nonparametric Mann–Whitney U test 
was approximately 0.0026. That is, both tests confirm the 
result of a significant difference between age groups A and 
B as to the CLBSA distribution.
Influence of various genetic polymorphisms 
on doxorubicin clearance
The influence of several known genetic polymorphisms 
occurring in eight genes encoding for proteins involved 
in doxorubicin metabolism or transport (ABCB1, 
ABCC1, CBR1, CBR3, NQ01, SLC22A16, SLC28A3 
and UGT2BT) was analyzed. The percentage of homozy-
gous individuals ranged from 0 to 26, 5 % [mean: 10.1 %], 
the one of heterozygous individuals from 10.2 to 59.2 % 
[mean: 34.9 %]. Although we detected quite a high number 
of polymorphisms and although increasing evidence exists 
that doxorubicin-induced cardiotoxicity can be predicted 
by pharmacogenomics analysis [3, 4], no influence of any 
of the investigated gene polymorphisms on the doxorubicin 
pharmacokinetics could be observed in the population PK 
model. An overview of the investigated polymorphisms 
along with the numbers of individuals being of wild-type, 
heterozygous or homozygous genotype is found in Online 
Resource 3.



















Fig. 3  Age dependency of doxorubicin clearance. Distribution of 
clearance (CL) (normalized to BSA) for the two investigated age 
groups (A: <3 years and B: 3 to <18 years). Data are summarized as 
box-and-whisker plots. In each plot, the central box represents values 
from the lower to upper quartile (25–75 percentiles) and the middle 
line the median. The end of the upper whisker corresponds to the 
largest observation smaller than the 75 % quantile + 2*IQR. Like-
wise, the end of the lower whisker corresponds to the smallest obser-
vation larger than the 25 % quantile − 2*IQR. Observations that are 
beyond the whiskers can be regarded as outliers
Fig. 4  Biomarker concentrations of NT-proBNP and cTnT before 
and after doxorubicin administration. NT-proBNP (a exemplary for 
the three natriuretic peptides) and cTnT (b exemplary for the two 
cardiac troponins) concentrations in plasma samples before (Sam-
ples A and C) and at different times after doxorubicin administration 
(samples B, D, E). Data are summarized as box-and-whisker plots as 
explained in Fig. 3
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Natriuretic peptides and cardiac troponins as markers 
for doxorubicin‑induced subclinical cardiotoxicity
Pre- and post-dose levels of both sampling periods (SP) 
were compared for two troponins (cTnT and cTnI) and 
three natriuretic peptides (BNP, NT-proBNP and NT-
proANP) to determine whether the biomarker blood con-
centrations showed an increase after administration of dox-
orubicin. Post-dose levels (samples B and D) were drawn 
up to 2 days after end of doxorubicin administration with 
more than 50 % of the samples drawn between 22 and 25 h 
after end of administration (time after dose, mean sample 
(B): 23.8 h; mean sample (D): 21.6 h). A clear correla-
tion was observed between the three natriuretic peptides, 
with the highest correlation between NT-proBNP and BNP 
and a slightly lower correlation between NT-proANP and 
the two BNP variants (Online Resource 4). A strong cor-
relation could also be detected between the two examined 
troponins, whereas only medium to low correlations exist 
between the troponins and the natriuretic peptides.
Blood concentrations for all three natriuretic peptides 
increased noticeably compared to pre-dose levels (p < 0.001 
for both the first and second SP for all three natriuretic pep-
tides, Wilcoxon’s signed rank test) (Fig. 4a, NT-proBNP, 
exemplary for the three natriuretic peptides). In contrast, 
cTnT or cTnI was not noticeably elevated immediately 
after doxorubicin administration (cTnT: first SP p = 0.764, 
second SP p = 0.576; cTnI: first SP p = 0.951, second SP 
p = 0.035), but 2–4 weeks after the second sampling cycle 
(cTnT: p < 0.001, cTnI < 0.01), showing a delayed increase 
in cardiac troponin blood concentrations (Fig. 4b, cTnT, 
exemplary for both cardiac troponins).
Cardiac troponin blood concentrations correlated with 
administered cumulative doxorubicin dose normalized to 
BSA (cTnT: Spearman’s correlation: 0.409, p value <0.001; 
cTnI: Spearman’s correlation: 0.452, p value <0.001). A 
minor increase in blood concentration between sample 
A and E was also observed for NT-proBNP (p = 0.026), 
but not for the other two measured natriuretic peptides 
(BNP: p = 0.449; NT-proANP: p = 0.716). Furthermore, 
a marginal correlation to cumulative dose was observed for 
BNP (Spearman’s correlation: 0.371, p value <0.001), NT-
proBNP (Spearman’s correlation: 0.242, p value: 0.023) 
and NT-proANP (Spearman’s correlation: 0.256, p value = 
0.016).
We furthermore assessed the correlation between the 
pre–post-differences in natriuretic peptide concentrations 
(i.e., before and after doxorubicin administration for each 
sampling period) and the individual doxorubicin dose 
intensity in each cycle (Table 2) represented by the AUC 
(area under the curve) and Cmax. No correlation could be 
detected for Doxo AUC, but small negative correlations 
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natriuretic peptides and Cmax. Since the correlation coef-
ficients are small, the tests were not adjusted for multiple 
testing and a lot of confounder might interfere with this 
observation, these differences are difficult to explain and 
might also be arisen by chance.
Furthermore, we could not detect any correlation 
between the difference in cardiac troponin plasma concen-
trations (between sampling times E and A) with the doxo-
rubicin dose (normalized to BSA) administered as well 
as with the calculated sums of AUCs for that time frame 
(Table 2).
Analysis of left ventricular shortening fraction (LVSF)
Data on the cardiac function were determined at the begin-
ning (echo 1.1) and end (echo 2.2) of the trial. The mean 
LVSF values at echo 1.1 were 39 ± 8.1 % and the ones 
at Echo 2.2 37.6 ± 6.6 %, showing that for the doxo-trial 
patient collective subclinical cardiac function did not 
decrease severely throughout the trial period. Anyhow, six 
patients had throughout the study one LVSF value below 
28 % and 20 patients had one or more LVSF values ≤30 %. 
Both are considered abnormal values. Furthermore, LVSF 
values of echo 2.2 negatively correlated with administered 
cumulative doxorubicin dose normalized to BSA [Spear-
man’s correlation: −0.567, p value <0.001].
Discussion
It may be surprising to investigate a drug with decades of 
clinical experience, but doxorubicin highlights the com-
plexity of pediatric drug development and the difficulties 
to implement this development into the drug regulatory 
framework. The drug is highly effective and its use has 
contributed significantly to increasing the cure rate for chil-
dren with cancer. This success has mainly been driven by 
investigator-initiated trials in which treatment strategies 
and dosing rules were developed empirically rather than 
establishing dosing schemes based on systematic investiga-
tions of the influence of patient size and age.
Increasing cure rates were accompanied by increas-
ing recognition of dose-dependent severe side effects, 
long-term toxicity and risk of chronic cardiac failure. Very 
young patients remained the group with the weakest evi-
dence for age-appropriate dosing, although they are also 
the group with the highest uncertainties about the risks of 
doxorubicin exposure.
Acknowledging the need to study pharmacokinetics of 
doxorubicin in children, the EPOC consortium obtained 
funding within the 7th EU framework program. The result-
ing study was an add-on trial to the present disease-related 
national or European treatment protocols. These protocols 
vary largely concerning doxorubicin dosage, infusion times, 
chemotherapy regimen and concomitant medications, not 
only between the various cancer types but also between dif-
ferent countries. The doxo-trial thus comprised the wide 
range of existing clinical practice. To deal with this, het-
erogeneity was only possible by a) using a population PK 
approach, b) assuming a linear pharmacokinetic for doxo-
rubicin and c) defining standard procedures for doxorubicin 
administration and blood sampling to minimize pre-ana-
lytical mistakes [16, 17]. With this approach, it was possi-
ble to combine data from patients receiving different doses 
and infusion times in one analysis and the primary question 
of the trial, whether there is a difference in the distribution 
of the clearances of the age groups <3 years and those 3 to 
<18 years could be addressed. A significant difference was 
identified with the BSA-normalized clearance being lower in 
the younger age group, meaning that similar dose calculation 
rules lead to higher dose intensity in the younger patients. 
As mentioned before, in most cancer therapy protocols, 
the dose is already reduced in the very young children, but 
dose reduction strategies vary largely between the differ-
ent national or European treatment protocols. Our results 
strongly support these dose reductions. Anyhow, the analy-
sis of PK parameters is only one of several aspects defining 
the optimal dosage. The actual clinical significance needs to 
be defined in specific clinical trials focusing on this issue. 
Our PK model can be used to develop a suggestion for an 
adequate and standardized dose reduction strategy. This is 
methodologically very demanding and needs scientific dis-
cussion taking pharmacological surrogates and clinical goals 
into account [18], which is ongoing right now. The suggested 
dose reduction strategy needs to be validated in clinical stud-
ies which is why it is an urgent need to bring these studies 
back on the agenda’s of the concerned trial groups.
Besides PK, the “doxo”-study explored the role of 
natriuretic peptides and cardiac troponins as potential early 
predictors for subclinical and eventually long-term car-
diotoxicity. Although we observed a direct response for all 
three natriuretic peptides after drug application, we cannot 
exclude that this acute increase in plasma level may be due 
to stress from hospitalization and chemotherapy, raised fluid 
volume or other confounders at this point. Moreover, none 
or only weak correlations between raised biomarker levels 
and individual doxorubicin dose intensity (represented by 
AUC and Cmax) could be identified. Cardiac troponin did 
not directly respond to single doxorubicin applications, but 
plasma concentrations determined 1–2 weeks after doxoru-
bicin administration showed a slight but statistically notice-
able increase. Furthermore, cardiac troponin concentrations 
correlated with administered cumulative doxorubicin dose, 
which is the major risk factor for doxorubicin-induced car-
diotoxicity. These observations match to the report from 
Lipshultz et al. observing an increase in the percentage of 
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patients with at least one elevated cTnT level with time of 
cancer treatment [19] and might be a hint that cTnT might 
be a suitable prognostic marker for anthracycline-induced 
cardiotoxicity. It therefore would be interesting to introduce 
measurements of cTnT or cTnI, which largely correlated in 
our study, into further studies, e.g., disease-specific cancer 
trials, and follow changes in blood concentrations over the 
whole chemotherapy for each patient, since a big limitation 
of our study with respect to the pharmacodynamic surro-
gates was the short trial duration for each patient. Another 
limitation was the small number of patients. Since echocar-
diography itself is not a very sensitive prognostic marker for 
late cardiac effects, verification of a cardiotoxic biomarker 
can only be done by correlation to late cardiac events. Since 
these occur in less than 10 % of patients, the number of 
patients recruited in the doxo-trial is too low to allow reli-
able predictions. EPOC is nevertheless discussing possi-
bilities with late effect groups and authorities on how long-
term follow-up can be organized. It would be interesting to 
recheck the amount of doxorubicin dose intensity (AUC and 
Cmax) as well as biomarker blood levels for patients with 
late subclinical or clinical cardiac events.
In summary, the trial substantiated the existing dose 
reduction strategies for infants and should serve as a step 
forward toward standardized age-dependent dosing for 
young children. In addition, dose calculation, age-depend-
ent pharmacodynamics and clinical needs require an inten-
sified focus and prospective evaluation within the respec-
tive clinical trials.
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